Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

NCT02896192 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Pro-opiomelanocortin (POMC) Deficiency Obesity

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.